Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

SGYP 3.02 +0.04 (1.34%)
price chart
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10%
Synergy Pharmaceuticals, Inc. (SGYP - Snapshot Report) was a big mover last session, as the company saw its shares rise 10% on the day.
Related articles »  
Synergy Pharmaceuticals Inc (SGYP) is Trading Higher on Unusual Volume for ...
Synergy Pharmaceuticals Inc ($SGYP) experienced unusually high volume on Feb. 27, as the stock gained 1.34% to a closing price of $3.02.
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of ...
Related articles »  
Zacks Long Term Rating Update on Synergy Pharmaceuticals Inc
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) remains a strong buy in the latest set of rankings. The counter has received an average rating of 1 by 2 analysts.
Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million ...
Related articles »  
Synergy Pharmaceuticals Inc Receives Average Target Price of $7.25
Synergy Pharmaceuticals Inc (NASDAQ:SGYP): 2 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $7.25 in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). However, the stock price could fluctuate by $ 1.77 from ...
Synergy Pharmaceuticals Inc Registers High Short Percent of Float
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is in a strong bear grip; the short interest is registered high at 14.09% of the floated shares.
Shares of Synergy Pharmaceuticals Inc Soars by 1.39% for the Week  Ashburn Daily
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences  Business Wire (press release)
Analyst Rating Update on Synergy Pharmaceuticals Inc
As many as 2 brokerage firms have rated Synergy Pharmaceuticals Inc (NASDAQ:SGYP) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term.
Synergy's Constipated Share Price Is Headed For A Cure
Synergy Pharmaceuticals (NASDAQ:SGYP) shareholders have not been living a charmed life of late. When I first wrote ... Analysts will pound the table of Plecanatide success and the company will begin to speak of commercial approval. The second Phase III ...
Synergy Pharmaceuticals Inc (SGYP), Proteon Therapeutics Inc (PRTO): James ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E. Flynn's Deerfield Management and Peter Kolchinsky's RA Capital Management started new stakes in them lately.
Related articles »